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A Mathematical Investigation on Tumor-Immune Dynamics: The Impact of
Vaccines on the Immune Response
Jonathan Quinonez,
1Larkin

INTRODUCTION
• An effective way to cure disease is to prevent
the development of it all together.
• One modality to combat disease is cancer
vaccines that would “program” an individual’s
immune system to recognize foreign antigens
by stimulating cytotoxic T lymphocytes (CTL)
to attack cancer cells expressing a certain
tumor antigen [1-5].
• Current vaccine strategies to combat cancer
include vaccines consisting of lymphocytes,
which include: helper T lymphocytes (Th),
dendritic cells (DC), macrophages, or
reprogrammed oncolytic viruses [1,2].
• We developed a mathematical model of tumor
dynamics in response to a vaccine injection
composed of lung cancer epitopes (Survivin,
Kita-Kyushu lung cancer antigen 1 (KKLC1),
and epidermal growth factor receptor (EGFR))
of different fragment sizes (8-12 amino acids
(aa) long) with the goal of determining which
epitopes produce a strong immune response.

METHODOLOGY
• The dynamics of the mathematical model, as
well as parameter values, are borrowed from
assertions, prior mathematical models, as well
as through parameter estimation through
numerical simulations.
• Our model is based on a previous model
published by de Pillis et al. [9], but expanded
to include simplified T cell development and
more cell populations to better depict the
immune response to cancer.
• No patient data was integrated into this model
yet as this model is in its infancy; a literature
review shows no prior model with an
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integrated MonteCarlo simulator.
• Generated data now is theoretical but has
applicability to the clinical setting. The
basis for the model is listed below.

METHODS
• The dynamics of the mathematical model, as
well as parameter values, are borrowed from
assertions, prior mathematical models, as well
as through parameter estimation through
numerical simulations.
• Our model is based on a previous model
published by de Pillis et al. [9], but expanded to
include simplified T cell development and
more cell populations to better depict the
immune response to cancer.
• No patient data was integrated into this model
yet as this model is in its infancy; a literature
review shows no prior model with an integrated
MonteCarlo simulator.
• This model has been modified further to
introduce the addition of lung cancer
“vaccines” using Monte-Carlo processes to
simulate an antigen stimulation response to
different HLA epitopes [9,13,19]. The model is
as follows:

FIGURES

• Equation #1 describes the change in population of a cancerous pathology in
which the state variable is C. Cancer populations propagate (rc) at a fixed rate
and die off due to cell-to-cell interactions between NK cells (k1), CTL’s (k2), and
macrophages (k3).
• Equation #2 describes the change of NK cell populations in which the state
variable of this equation is (N). NK cells are born at a fixed rate (Bn) and die off
(Dn) in proportion to population levels. In addition, NK cells are recruited in
response to cancer antigen presentation at a fixed rate (Rn and Mn) as well as
die off due to cell-cell interactions with cancer (Ln).

• Equation #3 describes the change of naive CD8 populations in which the state
variable of this equation is (Tn). Naive CD8 populations are born at a fixed rate
(Bt) and die off (Dt) in proportion to population levels. Such cells then transition
from the naive to primed states due to cancer antigen acquisition (Ma) by antigen
presenting cells at a fixed rate (Mt), which then present the processed cancer
antigen to naive populations.
• Equation #4 describes the change of primed CD8 populations in which the state
variable of this equation is (Te). Naive CD8 populations are primed with cancer
antigen transition from their naive to primed states to combat cancer (first term)
and die off (De) in proportion to population levels. Primed CTL populations are
then influenced due to memory cell recruitment by interlukin-2 (Rr) and are
inhibited (Ih) by T regulatory cells.
• Equation #5 describes the change of naive CD4 populations in which the state
variable of this equation is (Rn). Naive CD4 regulatory populations are born at a
fixed rate (Br) and die off (Dr) in proportion to population levels. Such cells then
transition from the naive to primed states due to cancer antigen acquisition (M a)
by antigen presenting cells at a fixed rate (Mt), which then present the processed
cancer antigen to naive populations.
• Equation #6 describes the change of primed CD4 populations in which the state
variable of this equation is (Re). Naive CD8 populations are primed with cancer
antigen transition from their naive to primed states to combat cancer (first term)
and die off (Dr) in proportion to population levels. Primed CTL populations are
then influenced due to memory cell recruitment by interlukin-2 (Rr) and are
inhibited (Ih) by T regulatory cells.
• Equation #7 describes the change of interleukin-2 concentration in which the
state variable of this equation is (I2). IL-2 is produced at a constant rate (Ci) by
primed immune cells, mainly of HTL lineage, and is consumed in varying
proportions (Rh ,Rt, and Rr) to recruit circulating memory cells to combat cancer
populations. In addition, IL-2 denatures (Di) in proportion to population levels.
• Equation #8 describes the change of antigen presenting cells in which the state
variable of this equation is (Ap). APC populations are primed (Ra) in direct
proportion to cancer antigen and die off (dA) in proportion to population levels.
•

Equation #9 describes the change of naive CD4 regulatory populations in
which the state variable of this equation is (Rn). Naive CD4 regulatory
populations are born at a fixed rate (Br) and die off (Dr) in proportion to
population levels. Such cells then transition from the naive to primed states due
to cancer antigen acquisition (Ma) by antigen presenting cells at a fixed rate
(Mt), which then present the processed cancer antigen to naive populations.

• Equation #10 describes the change of primed CD4 regulatory populations in
which the state variable of this equation is (Re). Naive CD4 regulatory
populations are primed with cancer antigen transition from their naive to primed
states to combat cancer (first term) and die off (Dr) in proportion to population
levels. Primed CTL populations are then influenced due to memory cell
recruitment by interlukin-2 (Rr).
• Equation #11 describes the change of macrophage populations in which the
state variable of this equation is (M). NK cells are primed at a rate (Ra) in
proportion to cancer antigen and die off (Dn) in proportion to population levels
as well as interactions with cancer cells (Ln) .
• Equations #12 and #13 act as placeholder equations for two variables (Rc and
Ma) that act as the Monte-Carlo Simulator via a pseudo-number generator that
affects the output of the other eleven equations

RESULTS AND DISCUSSION
• MHC class I molecules are designed to
recognize peptide fragments of about eight to
ten aa along with the maximum being 11.
• With the involvement of intracellular antigens
for cancer, the selection of the right HLA gene
complex depends on the sequence involved to
activate the system.
• Our results illustrate that amino acid epitopes
between 8-11 aa long will produce a robust
immune response, while anything not in this
estimated range will produce a non-robust
immune response.
• This model, although useful in predicting the
long-term status of a patient, cannot effectively
predict which antigen epitopes and HLA
combinations will produce a strong immune
response due to the current nature of the model.

CONCLUSION
• In our model, three antigens Survivin, KKLC1,
and EGFR [24] were utilized from the
TANTIGEN database to predict an immune
response once cancer was detected within an
individual following utilization of a synthetic
vaccine.
• We applied mathematical modeling as a tool to
depict the strength of a host’s immune
response after it has been subjected to a lung
tumor vaccine.
• Here, we showed and can infer that if a
synthetic epitope is not between 8-11 aa long,
a host will produce an immune response, but
that is not ideal to the elimination of cancer
[26,27].
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